Biomerica (BMRA) Competitors

Trinity Biotech (NASDAQ:TRIB) and Biomerica (NASDAQ:BMRA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, community ranking, dividends, profitability, valuation, media sentiment and analyst recommendations.

Does the MarketBeat Community believe in TRIB or BMRA?

Trinity Biotech received 180 more outperform votes than Biomerica when rated by MarketBeat users. Likewise, 70.92% of users gave Trinity Biotech an outperform vote while only 67.82% of users gave Biomerica an outperform vote.

Company	Underperform	Outperform
Trinity Biotech	Outperform Votes 317 70.92%	Underperform Votes 130 29.08%
Biomerica	Outperform Votes 137 67.82%	Underperform Votes 65 32.18%

Is TRIB or BMRA more profitable?

Trinity Biotech has a net margin of -42.26% compared to Trinity Biotech's net margin of -117.46%. Biomerica's return on equity of 0.00% beat Trinity Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trinity Biotech	-42.26%	N/A	-36.02%
Biomerica	-117.46%	-64.00%	-50.95%

Do analysts recommend TRIB or BMRA?

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trinity Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
Biomerica	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A

Do institutionals & insiders have more ownership in TRIB or BMRA?

79.0% of Trinity Biotech shares are owned by institutional investors. Comparatively, 22.3% of Biomerica shares are owned by institutional investors. 8.2% of Trinity Biotech shares are owned by insiders. Comparatively, 13.5% of Biomerica shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Which has more risk and volatility, TRIB or BMRA?

Trinity Biotech has a beta of 1.21, indicating that its stock price is 21% more volatile than the S&P 500. Comparatively, Biomerica has a beta of -1.04, indicating that its stock price is 204% less volatile than the S&P 500.

Which has higher earnings & valuation, TRIB or BMRA?

Biomerica has lower revenue, but higher earnings than Trinity Biotech. Biomerica is trading at a lower price-to-earnings ratio than Trinity Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trinity Biotech	$56.83M	0.25	-$24.02M	-$3.17	-0.58
Biomerica	$5.34M	2.46	-$7.14M	-$0.37	-2.11

Does the media favor TRIB or BMRA?

In the previous week, Biomerica had 6 more articles in the media than Trinity Biotech. MarketBeat recorded 7 mentions for Biomerica and 1 mentions for Trinity Biotech. Biomerica's average media sentiment score of 0.00 beat Trinity Biotech's score of -0.02 indicating that Trinity Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trinity Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Biomerica	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Trinity Biotech beats Biomerica on 10 of the 15 factors compared between the two stocks.